There are limited treatment options available for patients living with non-diabetic CKD, and the unmet need is high for new treatments to delay kidney disease progression and reduce cardiovascular risk
Previously, Arexvy was authorized for adults 60 and older, and for those 50–59 with heightened risk
Under the agreement, healthcare professionals in the country will gain access to C2N’s PrecivityAD2 blood test
Desidustat tablets are a novel oral HIF-PHI approved for treating anaemia in non-dialysis adult CKD patients
Diasens and GlucoLive are designed for diabetic, Chronic Kidney Disease (CKD), and post-transplant patients who require continuous glycaemic surveillance and integrated remote care
The new facilities are designed to provide focused, patient-centric care through advanced diagnostics, minimally invasive treatments, and multidisciplinary expertise
The collaboration will leverage this clinical experience to inform NCEL-101 development, streamline regulatory pathways, and potentially accelerate timelines for achieving durable graft survival comparable to donor human islets
The two companies will collaborate to evaluate Hopewell’s ttLNPs for clinical applications
Subscribe To Our Newsletter & Stay Updated